Massive study aims to decode lung disease progression

NCT ID NCT07178392

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study will observe 2,864 people with idiopathic pulmonary fibrosis (IPF) to learn how the disease changes over time and how it relates to traditional Chinese medicine syndromes. Researchers will track lung function, exercise ability, quality of life, and other health markers. The goal is to better understand IPF at different stages, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help doctors better understand how IPF progresses and improve how they classify and treat the disease.

What could go wrong

This is an observational study, not a treatment trial. It will not test any new drug or therapy, so it cannot directly improve patient outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of Henan University of Chinese Medicine

    Zhengzhou, Henan, 450000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••